| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300760.CN | Shenzhen Mindray Bio-Medical Electronics | 62.1 | $42,453 | CN |
| 688506.CN | Sichuan Biokin Pharmaceutical Co., Ltd. | 57.4 | $12,282 | CN |
| 000999.CN | China Resources Sanjiu Medical & Pharmac | 64.1 | $7,824 | CN |
| 300832.CN | Shenzhen New Industries Biomedical Engin | 64.1 | $7,489 | CN |
| 301301.CN | Yili Chuanning Biotechnology Co., Ltd. C | 74.5 | $4,034 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 69.9 | $586 | CN |
| 688566.CN | Jiangsu Jibeier Pharmaceutical Co. Ltd. | 60.5 | $658 | CN |
| 688581.CN | Hangzhou AGS MedTech Co. Ltd. | 66.5 | $695 | CN |
| 603439.CN | GuiZhou SanLi Pharmaceutical Co., Ltd. C | 72.3 | $783 | CN |
| 688253.CN | Innovita Biological Technology Co., Ltd. | 82.4 | $789 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 000999.CN | China Resources Sanjiu Medical & Pharmac | 64.1 | 17 | CN |
| 600566.CN | HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Cl | 65.6 | 15 | CN |
| 300009.CN | Anhui Anke Biotechnology (Group) Co., Lt | 58.1 | 10 | CN |
| 300595.CN | Ovctek China, Inc. Class A | 49.2 | 10 | CN |
| 000915.CN | Shandong Wit Dyne Health Co., Ltd. Class | 53.9 | 9 | CN |
| 600211.CN | Tibet Rhodiola Pharmaceutical Holding Co | 60.2 | 8 | CN |
| 600285.CN | Henan Lingrui Pharmaceutial Co., Ltd. Cl | 66.0 | 6 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 69.9 | 5 | CN |
| 600779.CN | Sichuan Swellfun Co., Ltd. Class A | 70.7 | 5 | CN |
| 002773.CN | Chengdu Kanghong Pharmaceutical Group Co | 60.4 | 4 | CN |
| Average Market Cap | $4,008 |
| Median Market Cap | $1,851 |
| Avg. 3 Mo. Dollar Vol. | $38,293,469 |
| Avg. 3 Mo. Trading Vol. | 8,145,666 |
| Last Rebalance Date | 06/17/2024 |
| Companies Replaced | 13 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 19.4 |
| Forward P/E Ratio (12 Mo.) | 19.2 |
| Price/Book Ratio | 3.6 |
| Avg. Revenue Chg. - 3 Yr | 54.6% |
| Avg. Op. Income Chg. - 3 Yr. | 83.0% |
| Avg. EPS Growth - 3 Yr. | 22.8% |
| Avg. EPS Growth - 1 Yr. | 22.5% |
| Avg. Operating Margin | 30.2% |
| Avg. LT Debt to Total Capital | 1.9% |
| Avg. Return on Equity | 19.4% |
| Dividend Yield | 1.6% |
| China Health Care Index | 64.68 |
| China | 100.0% |
